UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000039587
Receipt No. R000045107
Scientific Title Effect test of continuous intake of test food for 8 weeks on endurance and fatigue in healthy adult women
Date of disclosure of the study information 2020/03/05
Last modified on 2020/07/30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Effect test of continuous intake of test food for 8 weeks on endurance and fatigue in healthy adult women
Acronym Effect test of continuous intake of test food for 8 weeks on endurance and fatigue in healthy adult women
Scientific Title Effect test of continuous intake of test food for 8 weeks on endurance and fatigue in healthy adult women
Scientific Title:Acronym Effect test of continuous intake of test food for 8 weeks on endurance and fatigue in healthy adult women
Region
Japan

Condition
Condition Healthy subjects
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The purpose of this study is to examine the effects on endurance and fatigue of Japanese women aged between 40 and 70 years old by taking test foods continuously for 8 weeks.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes 1)Primary efficacy assessment
VAS questionnaire
Key secondary outcomes 2)Secondary evaluation of effectiveness
POMS2 shortened version,body composition,shuttle stamina walk test

3)Safety evaluation
Vital signs,biochemical tests, hematological tests,adverse events

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 8-week intake of the test food
Interventions/Control_2 8-week intake of the placebo food
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
40 years-old <=
Age-upper limit
70 years-old >
Gender Female
Key inclusion criteria 1.Healthy Japanese female aged 40 years or older and younger than 70 years at the time of the informed consent.
2.Subject who feels tired on a daily basis.
3.Subject who usually takes three meals a day.
4.Subject who has understood the purpose of the study, and agreed to participate it by signing the written informed consent.
Key exclusion criteria 1.Heavy drinker
2.Subject who has strong exercise habits.
3.Subject who has experienced chest pain or abnormal pulse at rest.
4.Subject who frequently has palpitations, shortness of breath, lightheadedness, dizziness or loss of consciousness.
5.A family member who has died suddenly for unknown reasons.
6.Subject who has been diagnosed as having problems with the legs.
7.Subject who is receiving the rheumatism treatment.
8.Subject with a history of knee surgery or disease, or who regularly use of cane.
9.Subject with severe hay fever symptoms affecting fatigue.
10.Subject whose protein intake is restricted by a doctor (including mild restrictions).
11.Subject who is taking medication or under medical treatment because of some serious disease.
12.Subject who is under exercise therapy or dietetic therapy.
13.Subject who has an allergy for test food(27 items: milk, soy).
14.Subject who has or had a history of either medicine or alcohol dependence syndrome.
15.Subject who has or had a history of mental illness (depression) or sleep disturbance.
Target sample size 30

Research contact person
Name of lead principal investigator
1st name Daisuke
Middle name
Last name Ochitani
Organization HUMA R&D CORP
Division name Clinical Development Division
Zip code 108-0014
Address Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan
TEL 03-3431-1260
Email ochitani@huma-rd.co.jp

Public contact
Name of contact person
1st name Daisuke
Middle name
Last name Ochitani
Organization HUMA R&D CORP
Division name Clinical Development Division
Zip code 108-0014
Address Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan
TEL 03-3431-1260
Homepage URL
Email ochitani@huma-rd.co.jp

Sponsor
Institute HUMA R&D CORP
Institute
Department

Funding Source
Organization CHARLE CO.,LTD.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Ethics Committees of Nihonbashi Egawa Clinic
Address 2F Kotobuki Build. 1-1-3 Yaesu Chuo-ku, Tokyo 103-0028 Japan
Tel 03-5204-0311
Email jim@medipharma.co.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2020 Year 03 Month 05 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2020 Year 02 Month 07 Day
Date of IRB
2020 Year 02 Month 14 Day
Anticipated trial start date
2020 Year 02 Month 26 Day
Last follow-up date
2020 Year 05 Month 01 Day
Date of closure to data entry
2020 Year 05 Month 07 Day
Date trial data considered complete
2020 Year 05 Month 21 Day
Date analysis concluded
2020 Year 07 Month 27 Day

Other
Other related information (Exclusion criteria continued)
16.Subject who has irregular work rhythms such as working at night and shift work.
17.Subject who has extremely irregular lifestyle such as eating and sleeping.
18.Subject who has an unbalanced diet.
19.Subject who has or had a history of severe diseases such as brain disease, malignant tumor, immune disease, diabetes, liver disease (hepatitis), kidney disease, heart disease, thyroid disease, adrenal disease, other metabolic diseases.
20.Subject who uses health foods, supplements, and pharmaceuticals that affect protein metabolism (including protein) or reduce fatigue.
21.Subject who has participated in other clinical studies within the past 3 months from the day of the consent acquisition or who is planning to participate in other clinical studies during the current study.
22.Subject who has blood drawn or blood component more than 200mL within the past 1 months or more than 400mL within the past 3 months from the day of the consent acquisition.
23.Subject who is planning to get pregnant after the day of informed consent or is currently pregnant and lactating.
24.Subject who can't keep the daily records.
25.Subject who is judged as an inappropriate candidate according to the screening data.
26.Subject who is considered as an inappropriate candidate by the doctor in charge.

Management information
Registered date
2020 Year 02 Month 25 Day
Last modified on
2020 Year 07 Month 30 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045107

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.